India, June 12 -- Kyntra Bio (KYNB), a biopharmaceutical company, on Thursday released new data from the Phase 3 MATTERHORN trial for Roxadustat in treating anemia associated with lower-risk myelodysplastic syndrome.
Myelodysplastic syndromes (MDS) are characterized by dysfunctional progenitor blood cells and stem cells, causing chronic anemia. About 80% of MDS patients have anemia at the time of diagnosis, and 50% require regular blood transfusions. About 77% of patients are considered lower-risk MDS (MDS) due to the low incidence of the disease.
Roxadustat is an oral medication developed to increase endogenous production of the erythropoietin protein, which promotes erythropoiesis, improved iron absorption and mobilization. The drug has...